866-997-4948(US-Canada Toll Free)

Swine Influenza - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Wine

No. of Pages : 38 Pages


Global Markets Directs, \'Swine Influenza Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Swine Influenza, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Swine Influenza. Swine Influenza Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Swine Influenza.
  • A review of the Swine Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Swine Influenza pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Swine Influenza.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Swine Influenza pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Swine Influenza Overview 6
Therapeutics Development 7
Pipeline Products for Swine Influenza - Overview 7
Pipeline Products for Swine Influenza - Comparative Analysis 8
Swine Influenza - Therapeutics under Development by Companies 9
Swine Influenza - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Swine Influenza - Products under Development by Companies 14
Swine Influenza - Companies Involved in Therapeutics Development 15
Novartis AG 15
OPKO Health, Inc. 16
Aprogen, Inc. 17
Pike Pharma GmbH 18
Greffex, Inc. 19
Lakewood-Amedex Inc. 20
Swine Influenza - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 27
Assessment by Therapeutic Class 29
Drug Profiles 31
H3N2c Vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Flu Vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Influ-nRNA - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
GREFLU/CAL - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Fluinhibit - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AP-302 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36

Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Table


Number of Products under Development for Swine Influenza, H2 2013 7
Number of Products under Development for Swine Influenza - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Comparative Analysis by Unknown Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Swine Influenza - Pipeline by Novartis AG, H2 2013 15
Swine Influenza - Pipeline by OPKO Health, Inc., H2 2013 16
Swine Influenza - Pipeline by Aprogen, Inc., H2 2013 17
Swine Influenza - Pipeline by Pike Pharma GmbH, H2 2013 18
Swine Influenza - Pipeline by Greffex, Inc., H2 2013 19
Swine Influenza - Pipeline by Lakewood-Amedex Inc., H2 2013 20
Assessment by Monotherapy Products, H2 2013 21
Number of Products by Stage and Target, H2 2013 23
Number of Products by Stage and Mechanism of Action, H2 2013 25
Number of Products by Stage and Route of Administration, H2 2013 26
Number of Products by Stage and Molecule Type, H2 2013 28
Number of Products by Stage and Therapeutic Class, H2 2013 30

List of Chart


Number of Products under Development for Swine Influenza, H2 2013 7
Number of Products under Development for Swine Influenza - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Early Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 21
Number of Products by Top 10 Target, H2 2013 22
Number of Products by Stage and Top 10 Target, H2 2013 23
Number of Products by Top 10 Mechanism of Action, H2 2013 24
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 25
Number of Products by Top 10 Molecule Type, H2 2013 27
Number of Products by Stage and Top 10 Molecule Type, H2 2013 28
Number of Products by Top 10 Therapeutic Class, H2 2013 29
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *